The primary objective of this study is to compare the effect of mitapivat versus placebo on anemia in pediatric participants with alpha- or beta-non-transfusio…

Non-Transfusion-dependent Alpha-ThalassemiaNon-Transfusion-dependent Beta-Thalassemia

~Estimated

~$10 – $8,750

Agios Pharmaceuticals, Inc.NCT07517133

Phase 3

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Subjects With α- or β- Transfusion-Dependent Thalassemia

The primary objective of this study is to compare the effect of mitapivat versus placebo on transfusion burden in pediatric participants with α- or β-transfusi…

Transfusion-dependent Alpha-ThalassemiaTransfusion-dependent Beta-Thalassemia

~Estimated

~$10 – $8,750

Agios Pharmaceuticals, Inc.NCT07506863